22nd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Event Date: April 29 - May 2, 2019

Event Location: Washington Hilton, 1919 Connecticut Ave, NW, Washington DC, 20009

Diapharma will is planning to attend the 22nd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting this year. Please click here to schedule a meeting with us or email us directly.

About the 22nd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. As the leading American conference focusing solely on gene and cell therapy, ASGCT’s annual meeting brings together more than 3400 professionals including scientists, physicians, and patient advocates.

ASGCT 2019 Topics

CAR T and Related Immune Effector Cell Therapies Workshop

Clinical Long Term Follow-Up

Now that CAR T cells have been in clinical use for over 5 years, this session will focus on the clinical results and longer-term follow up of CAR T cell studies in hematologic malignancies, on the consensus grading systems that have emerged as CAR T cells enter general practice and there are more and more clinical studies, and on how clinical centers manage the administration and collection of long-term follow-up data required by regulatory bodies.

Novel Engineering and Gene Editing

This session will focus on the scientific innovation as well as the safety and regulatory aspects of next-generation genetic engineering strategies that are in development that will enable complex strategies to target novel antigens not amenable to standard autologous CAR T cell therapies or to enable allogeneic cellular products.

Beyond Autologous CAR-T Cells for Cancer

CAR T cells are in wide clinical use in B cell cancers as autologous cellular products that have been transduced to express a single transgene. This session will focus on innovations with alternative cellular products and indications, such as allogeneic NK cells, stem cells, and potential uses of engineered cell therapies on non-cancer indications.

Gene Editing Workshop

The Gene Editing workshop provides an overview of current gene editing technologies and approaches, emerging uses and applications, with sessions highlighting junior investigators and clinical gene editing programs.

Introduction to Gene Editing

NIH Genome Editing Consortium Grant Recipients

National Institutes of Health recently awarded its first grants through the Somatic Cell Genome Editing program

Corporate Reviews

A series of presentations from some of the leading companies in gene editing, describing their pre-clinical and clinical programs.

NIH Genome Editing Consortium Grant Recipients Continued

The National Institutes of Health recently awarded its first grants through the Somatic Cell Genome Editing program.

Gene editing is a dynamic area of research, attracting many new investigators.

A series of presentations from some of the leading companies in gene editing, describing their pre-clinical and clinical programs.

Pre-Approval Commercialization Workshop

The Pre-Approval Commercialization Workshop covers industry perspectives on CMC Challenges for cell and gene modified cell therapy products, updates from global regulatory bodies, manufacturing challenges in late phase development of gene therapy products, and discussions on the difficulties in commercializing AAV product candidates.

Global Regulatory Update: Outlook in 2019 – Policy Approaches and Considerations in Gene Therapy

Manufacturing Challenges During Late Phase Development of Gene Therapy Products

Hindrance to Commercializing AAV Product Candidates

Post-Approval Commercialization Workshop will include sessions on patient focused drug development; post-approval change management and overall impact on commercialization; and pricing, reimbursement, and payment models for gene therapies.

Bio Industry Symposium

Entering the Post-RAC Era Charting the Course of Cell & Gene Therapy Drug Development for the Future

Innovation in First Time in Human Study Clinical Studies

Pricing, Access, and Value of Gene Therapies

Nanoagents & Synthetic Formulations Symposium

Non-Viral Vectors and Immunity

Respiratory & GI Tract Symposium

Novel Strategies for Lung and GI Tract-directed Genetic Therapies

Adoptive T-Cell Therapy Education Session

Modalities of Genome Editing Education Session

Oncolytics Education Session

NK Cells Versus iNKT Cells Education Session

Induced Pluripotent Stem Cells Education Session

Cancer Scientific Symposium

Cancer Gene Therapies: Universal Cells, Targeted Vectors and Solid Tumor CART Efficacy

West Genome Editing Scientific Symposium

Gene Editing: From Platform Engineering to Assessing Impact of Innate and Adaptive Responses

Viral Gene Transfer Vectors Scientific Symposium

Vector Development, Clinical Implementation, and Corporate Connections

Translational Science and Product Development Scientific Symposium

Evaluating Gene & Cell Therapy Product Candidates

RNA Therapeutics Education Session

Design, Delivery, and Application of RNA Therapeutics

Cardiovascular Scientific Symposium

Beyond Cell Therapy: Extracellular vs. Multicellular Cardiovascular Regenerative Approaches

Immune Responses Scientific Symposium

Basic and Translational Aspects of Immunology and Gene and Cell Therapy

Neurologic & Ophthalmic Scientific Symposium

Genome Editing in the Retina and CNS

Translating non-viral Gene Delivery to Human Therapeutics

Genetic Modification of Stem Cells

Prophylactic and Therapeutic Antibodies against Infectious Diseases

Applications of Gene and Cell Therapy Technologies for Metabolic Diseases

Hematologic and Immunologic Scientific Symposium

Engineering Homing, Persistence and Potency in Cell Therapies

Commercializing Gene and Cell Therapies – Planning for Post-Approval Success and Pitfalls to Avoid

Gene Editing and Gene Modulation for Musculoskeletal Disease

Monroe Oligonucleotide and RNAi Therapeutics Scientific Symposium

Clinical Status of Oligonucleotide-based Drugs

About The ASGCT

The American Society of Gene & Cell Therapy (ASGCT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new genetic and cellular therapies. ASGCT was established in 1996 by Dr. George Stamatoyannopoulos, professor of medicine at the University of Washington’s School of Medicine and a group of the country’s leading researchers in gene therapy. With nearly 1,800 members in the United States and worldwide, ASGCT is the largest association of individuals involved in genetic and cellular therapeutics. ASGCT’s mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

Tomorrow, March 20, is the big day! #ASGCT19 abstract acceptance notifications go out to accepted first and presenting authors. Current Associate Members who are first and presenting authors are eligible for free registration to #ASGCT19! pic.twitter.com/T9dLY5mB46

— ASGCT (@ASGCTherapy) March 19, 2019

There's just barely more than 3 weeks left on early registration for #ASGCT19 (April 8) and 7 weeks out from the Annual Meeting itself (!!!). Join us April 29-May 2 for the premier event for professionals in #GeneTherapy and #CellTherapy. https://t.co/L7vYFasUeL pic.twitter.com/kPSj46tI1N

— ASGCT (@ASGCTherapy) March 14, 2019

#GeneTherapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human body—our genes. To understand how it works, we’ll start at the basics. https://t.co/fHdkiLanDR pic.twitter.com/DESZJ5W8MU

— ASGCT (@ASGCTherapy) January 17, 2019